Kidney Cancer
Also known as: Hypernephroma, Renal cancer, Kidney, Renal, Nephric
Methodology & AI Transparency ⓘ
Kidney Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: You have two kidneys.
- 2 Real-world patient consensus: Clinical coding for Kidney Cancer uses ICD-10 C64.9 across Cancer & Oncology specialty care.
- 3 Typical cash cost range: Clinicians assessing Kidney Cancer focus on local tissue remodeling [Kidney Cancer C64.9] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Kidney Cancer: maintaining Complete Blood Count in Kidney Cancer (C64.9: (ANC, Hemoglobin, Platelets)) within Safe hematologic reserve (C64.9).
Ask our AI Specialists anything about Kidney Cancer
What Is Kidney Cancer?
You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys. Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. You may have no symptoms at first. They may appear as the cancer grows.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Kidney Cancer (C64.9) features local tissue remodeling [Kidney Cancer C64.9]. Cross-referenced with NIH MeSH (Kidney Neoplasms), therapeutic stabilization in cancer & oncology is verified against Comprehensive Metabolic & in Kidney Cancer (C64.9: Organ Function Panel).
Common Symptoms & Clinical Signs
- • Blood in your urine
- • A lump in your abdomen
- • Presentation of Kidney Cancer (C64.9): unexplained bleeding, chronic in Kidney Cancer (C64.9: hoarseness/cough, or progressive)
- • Secondary Kidney Cancer clinical sign: abnormality detected early in Kidney Cancer (C64.9: on age-appropriate screening)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Kidney Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C64.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Kidney Cancer (C64.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C64.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Kidney Cancer (C64.9: Organ Function Panel) | Preserved renal/hepatic clearance (C64.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Kidney Cancer (C64.9: Genomic Staging) | Guideline-concordant surveillance (C64.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Kidney Cancer
Treatment selection for Kidney Cancer depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Kidney Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety and real-world benefits of Semaglutide in Patients With Chronic Kidney: What a 12,785-Participant Study Found Semaglutide demonstrates a favourable safety profile and significant cardiorenal benefits in CKD patients, with or without T2DM. Endocrinology, diabetes & metabolism • 2025-11-15 • Meta-Analysis | N = 12,785 | 99/100 | PMID 41276951 ↗ |
| New Insights on Heart and blood vessel and Kidney Outcomes and Mortality With Long-Acting: What a 71,351-Participant Study Found As a group, long-acting GLP-1RA, including both injectable and oral formulations, reduce incidence of MACE, HHF, and kidney events and all-cause mortality in T2D. Diabetes care • 2025-05-01 • Meta-Analysis | N = 71,351 | 99/100 | PMID 40156846 ↗ |
| Can This Approach Help? Inside the Latest Research on Intermittent or Continuous kidney-Replacement Therapy in Acute Kidney New England Journal of Medicine, Volume 395, Issue 17 , Page 1677-1690, October 29, 2026. New England Journal of Medicine • 2026-10-14 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 97/100 | PMID NEJM-62256824 ↗ |
| New Insights on Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart: What a 3,668-Participant Study Found Compared with placebo, a mean atrasentan exposure translated in a hazard ratio of 0.76 (95% confidence interval (CI): 0.28-0.85) for kidney events and 1.13 (95% CI: 1.03-2.20) for heart failure events. Clinical pharmacology and therapeutics • 2021-06-15 • Phase III Randomized Trial | N = 3,668 | 96/100 | PMID 33338269 ↗ |
| New Insights on Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney: What a 6,609-Participant Study Found 1995 participants (1035 placebo, 960 empagliflozin) had ≥1 ACH (1895 ACH in placebo and 1611 in the empagliflozin 10-mg groups). Clinical therapeutics • 2025-12-15 • Phase III Randomized Trial | N = 6,609 | 96/100 | PMID 41047325 ↗ |
Kidney Cancer Patient Community & “People Like Me” Threads
Filter Kidney Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.